Charles River Laboratories (CRL) valuation
Charles River Laboratories P/E ratio history
Charles River Laboratories has no meaningful price to earnings ratio at the last close, which happens when earnings over the last twelve months are negative or close to zero. At its last 8 fiscal year ends its P/E ranged from 23.0 (year to Dec 2022) to 48.6 (year to Dec 2021), with a median of 27.8.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 27, 2025 | $203.66 | -$2.91 | n/m | 18.9 |
| Dec 28, 2024 | $186.16 | $0.20 | n/m | 18.1 |
| Dec 30, 2023 | $236.40 | $9.22 | 25.6 | 21.2 |
| Dec 31, 2022 | $217.90 | $9.48 | 23.0 | 18.8 |
| Dec 25, 2021 | $369.20 | $7.60 | 48.6 | 33.1 |
| Dec 26, 2020 | $251.71 | $7.20 | 35.0 | — |
| Dec 28, 2019 | $151.93 | $5.06 | 30.0 | — |
| Dec 29, 2018 | $111.72 | $4.61 | 24.2 | — |
| Dec 30, 2017 | $109.45 | $2.54 | 43.1 | — |
| Dec 31, 2016 | $76.19 | $3.23 | 23.6 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Charles River Laboratories valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Charles River LaboratoriesCRL | $17.3B | — | 29.8 | 4.3 |
| Bio-TechneTECH | $11.4B | 62.6 | 35.7 | 9.4 |
| Mettler ToledoMTD | $33.8B | 37.8 | 33.8 | 8.2 |
| IQVIAIQV | $44.0B | 32.6 | 19.2 | 2.5 |
| WatersWAT | $45.4B | 115.4 | 29.7 | 9.8 |
| Agilent TechnologiesA | $49.4B | 34.4 | 26.5 | 6.7 |
| Peer median | 37.8 | 29.7 | 8.2 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: CRL financials · CRL returns
No forecast, no recommendation. This page describes Charles River Laboratories from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.